Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report

被引:1
|
作者
Li, Qizheng [1 ]
Zhang, Xia [1 ,2 ]
Fan, Buqun [1 ]
Yang, Yudie [1 ]
Cui, Xiaonan [1 ]
Zhang, Jie [1 ]
Jiang, Kaiteng [3 ]
Zhang, Chunxia [1 ]
Zhang, Bin [1 ]
机构
[1] Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian, Peoples R China
[2] Dalian Fifth Peoples Hosp, Dept Oncol, Dalian, Peoples R China
[3] Nanchang Univ, Queen Mary Coll, Nanchang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
TAS-102; anlotinib; third-line; case report; metastatic colon cancer; mCRC; COLORECTAL-CANCER; OPEN-LABEL; TRIFLURIDINE/TIPIRACIL TAS-102; ASIAN PATIENTS; DOUBLE-BLIND; PLACEBO; MONOTHERAPY; MULTICENTER; BEVACIZUMAB; SURVIVAL;
D O I
10.3389/fonc.2022.978005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer(mCRC), which has brought survival benefits to mCRC patients, however, disease progression is inevitable. More than 60% of patients still needed third-line treatment after the progress of second-line treatment. After the failure of second-line chemotherapy, treatment compliance and the physical tolerance of patients both decrease. Therefore, choosing an appropriate third-line treatment regimen is key to prolonging survival and improving quality of life. As a novel cytotoxic antitumor drug, trifluridine/tipiracil (TAS-102) is composed of trifluridine (FTD) and tipiracil hydrochloride (TPI). FTD can directly bind to the DNA of cancer cells to cause DNA dysfunction, thereby exerting antitumor effects. TPI can inhibit the degradation of FTD, thereby increasing its cytotoxicity. The few side effects of TAS-102 has become an important reason why clinicians present it as a treatment option to the patient for consideration, clinical trial data for progression free survival are lacking. The exploration of third-line treatment regimens with drug combinations has attracted much attention. This article reports a case of metastatic colon cancer (RAS/BRAF wild type, pMMR/Non-MSI-H), after failure of first-line and second-line therapies, the patient was eventually treated with anlotinib combined with TAS-102 as the third-line treatment. The treatment has shown good efficacy, with a long PFS benefit for more than 20 months and mild adverse reactions. This case reports demonstrates that anlotinib combined with TAS-102 is a promising third-line treatment regimen for refractory mCRC, and provides proof-of-concept for the clinical exploration of optimal third-line combination treatment regimens.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    [J]. ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [2] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    [J]. CANCER SCIENCE, 2018, 109 : 601 - 601
  • [3] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoichiro Yoshida
    Takeshi Yamada
    Hirohiko Kamiyama
    Chihiro Kosugi
    Keiichiro Ishibashi
    Hiroshi Yoshida
    Hideyuki Ishida
    Satoru Yamaguchi
    Hidekazu Kuramochi
    Atsuko Fukazawa
    Hiromichi Sonoda
    Kazuhiko Yoshimatsu
    Akihisa Matsuda
    Suguru Hasegawa
    Kazuhiro Sakamoto
    Toshiaki Otsuka
    Keiji Koda
    [J]. International Journal of Clinical Oncology, 2021, 26 : 111 - 117
  • [4] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoshida, Yoichiro
    Yamada, Takeshi
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Ishibashi, Keiichiro
    Yoshida, Hiroshi
    Ishida, Hideyuki
    Yamaguchi, Satoru
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Matsuda, Akihisa
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Koda, Keiji
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 111 - 117
  • [5] The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
    Kosugi, Chihiro
    Kamiyama, Hirohiko
    Yoshida, Yoichiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Fukazawa, Atsuko
    Matsuda, Akihisa
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Narushima, Kazuo
    Shuto, Kiyohiko
    Sakamoto, Kazuhiro
    Koda, Keiji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [6] Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report
    Kamei H.
    Ishibashi N.
    Tanigawa M.
    Yamaguchi K.
    Uchida M.
    Akagi Y.
    [J]. Journal of Medical Case Reports, 10 (1) : 1 - 5
  • [7] TAS-102 for the treatment of metastatic colorectal cancer
    Salvatore, Lisa
    Rossini, Daniele
    Moretto, Roberto
    Cremolini, Chiara
    Schirripa, Marta
    Antoniotti, Carlotta
    Marmorino, Federica
    Loupakis, Fotios
    Falcone, Alfredo
    Masi, Gianluca
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1283 - 1292
  • [8] Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study
    Li, Luchun
    Wang, Ting
    Wu, Zhijuan
    Li, Yan
    Ma, Huiwen
    Wang, Lulu
    Lei, Shuangyi
    Chen, Wen
    [J]. TRANSLATIONAL CANCER RESEARCH, 2023, 12 (11) : 3034 - 3044
  • [9] Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
    Cao, Jian-zhou
    Wu, Wei
    Pan, Jin-feng
    Wang, Hong-wei
    Jiang, Jun-hui
    Ma, Qi
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Treatment of TAS-102 in patients with metastatic colorectal cancer
    Ota, Takayo
    Tsukuda, Hiroshi
    Hasegawa, Yoshikazu
    Miyatake, Nozomi
    Suzumura, Tomohiro
    Fukuoka, Masahiro
    [J]. ANNALS OF ONCOLOGY, 2016, 27